File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1093/cid/ciy228
- Scopus: eid_2-s2.0-85054953932
- PMID: 29933437
- WOS: WOS:000442284400019
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Emergence of Integrase Resistance Mutations during Initial Therapy Containing Dolutegravir
Title | Emergence of Integrase Resistance Mutations during Initial Therapy Containing Dolutegravir |
---|---|
Authors | |
Keywords | antiretroviral therapy integrase strand transfer inhibitors. drug resistance |
Issue Date | 2018 |
Citation | Clinical Infectious Diseases, 2018, v. 67, n. 5, p. 791-794 How to Cite? |
Abstract | © The Author(s) 2018. Dolutegravir (DTG) is a preferred drug for initial treatment of human immunodeficiency virus type 1 infection. We present next-generation sequencing analysis of integrase genotypes during a period of virologic failure in a treatment-naive manwho initiated tenofovir disoproxil fumarate/emtricitabine plus DTG. |
Persistent Identifier | http://hdl.handle.net/10722/285818 |
ISSN | 2023 Impact Factor: 8.2 2023 SCImago Journal Rankings: 3.308 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fulcher, Jennifer A. | - |
dc.contributor.author | Du, Yushen | - |
dc.contributor.author | Zhang, Tian Hao | - |
dc.contributor.author | Sun, Ren | - |
dc.contributor.author | Landovitz, Raphael J. | - |
dc.date.accessioned | 2020-08-18T04:56:43Z | - |
dc.date.available | 2020-08-18T04:56:43Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Clinical Infectious Diseases, 2018, v. 67, n. 5, p. 791-794 | - |
dc.identifier.issn | 1058-4838 | - |
dc.identifier.uri | http://hdl.handle.net/10722/285818 | - |
dc.description.abstract | © The Author(s) 2018. Dolutegravir (DTG) is a preferred drug for initial treatment of human immunodeficiency virus type 1 infection. We present next-generation sequencing analysis of integrase genotypes during a period of virologic failure in a treatment-naive manwho initiated tenofovir disoproxil fumarate/emtricitabine plus DTG. | - |
dc.language | eng | - |
dc.relation.ispartof | Clinical Infectious Diseases | - |
dc.subject | antiretroviral therapy | - |
dc.subject | integrase strand transfer inhibitors. | - |
dc.subject | drug resistance | - |
dc.title | Emergence of Integrase Resistance Mutations during Initial Therapy Containing Dolutegravir | - |
dc.type | Article | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1093/cid/ciy228 | - |
dc.identifier.pmid | 29933437 | - |
dc.identifier.pmcid | PMC6093998 | - |
dc.identifier.scopus | eid_2-s2.0-85054953932 | - |
dc.identifier.volume | 67 | - |
dc.identifier.issue | 5 | - |
dc.identifier.spage | 791 | - |
dc.identifier.epage | 794 | - |
dc.identifier.eissn | 1537-6591 | - |
dc.identifier.isi | WOS:000442284400019 | - |
dc.identifier.issnl | 1058-4838 | - |